Topotecan monotherapy is indicated for the treatment of: • patients with metastatic carcinoma of the ovary after failure of first-line or subsequent therapy. • patients with relapsed small cell lung cancer (SCLC) for whom re-treatment with the first-line regimen is not considered appropriate (see section 5.1). Topotecan in combination with cisplatin is indicated for patients with carcinoma of the cervix recurrent after radiotherapy and for patients with Stage IVB disease. Patients with prior exposure to cisplatin require a sustained treatment-free interval to justify treatment with the combination (see section 5.1).
Pfizer Inc. and Hospira, Inc. announced that they have entered into a definitive merger agreement under which Pfizer will acquire...
The EU Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending the granting of a marketing...
Hospira, Inc. has announced that the company has received 510(k) regulatory clearance from the FDA for the Plum 360 infusion...
Pfizer Inc. announced that the European Commission (EC) has approved under the European Union (EU) Merger Regulation the company�s pending...
In a Complete Response Letter relating to Retacrit (epoetin alfa biosimilar) from Hospira/Pfizer ,the FDA has rejected the application citing...